EA202191404A1 - FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS - Google Patents

FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS

Info

Publication number
EA202191404A1
EA202191404A1 EA202191404A EA202191404A EA202191404A1 EA 202191404 A1 EA202191404 A1 EA 202191404A1 EA 202191404 A EA202191404 A EA 202191404A EA 202191404 A EA202191404 A EA 202191404A EA 202191404 A1 EA202191404 A1 EA 202191404A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antiviral agents
present
compounds
hepatitis
virus
Prior art date
Application number
EA202191404A
Other languages
Russian (ru)
Inventor
Джозеф ПАНАРЕСЕ
Декстер Дейвис
Сэмюэл Бартлет
Кэтрин Чон
Натаниэль Кентон
Ят Сунь Ор
Original Assignee
Энанта Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энанта Фармасьютикалс, Инк. filed Critical Энанта Фармасьютикалс, Инк.
Priority claimed from PCT/US2019/062372 external-priority patent/WO2020106816A1/en
Publication of EA202191404A1 publication Critical patent/EA202191404A1/en

Links

Abstract

В изобретении раскрыты соединения, имеющие формулу (I), или их фармацевтически приемлемые соликоторые ингибируют белок (белки), кодирующий вирус гепатита В (ВГВ), или нарушают работу клеточного цикла вируса гепатита В, а также могут применяться в качестве противовирусных средств. Настоящее изобретение касается также фармацевтических композиций, содержащих указанные выше соединения, для введения субъекту, страдающему инфекцией ВГВ. Настоящее изобретение касается также способов лечения инфекции ВГВ у субъекта путем введения фармацевтической композиции, содержащей соединения по настоящему изобретению.The invention discloses compounds having the formula (I), or their pharmaceutically acceptable solids, which inhibit the protein (s) encoding the hepatitis B virus (HBV), or disrupt the cell cycle of the hepatitis B virus, and can also be used as antiviral agents. The present invention also relates to pharmaceutical compositions containing the above compounds for administration to a subject suffering from HBV infection. The present invention also relates to methods of treating HBV infection in a subject by administering a pharmaceutical composition containing the compounds of the present invention.

EA202191404A 2019-08-08 2019-11-20 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS EA202191404A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962884486P 2019-08-08 2019-08-08
PCT/US2019/062372 WO2020106816A1 (en) 2018-11-21 2019-11-20 Functionalized heterocycles as antiviral agents

Publications (1)

Publication Number Publication Date
EA202191404A1 true EA202191404A1 (en) 2021-10-11

Family

ID=78572632

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191404A EA202191404A1 (en) 2019-08-08 2019-11-20 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS

Country Status (1)

Country Link
EA (1) EA202191404A1 (en)

Similar Documents

Publication Publication Date Title
PH12021551116A1 (en) Functionalized heterocycles as antiviral agents
PH12018550201A1 (en) Hepatitis b antiviral agents
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
PH12018550148A1 (en) Hepatitis b antiviral agents
EA202090514A1 (en) ANTI-VIRAL AGAINST HEPATITIS IN
MX2021003253A (en) Functionalized heterocycles as antiviral agents.
EA201891876A1 (en) TETRACYCLIC PYRIDONE COMPOUNDS AS ANTI-VIRUS MEANS
EA201892034A1 (en) ELIMINATION OF HEPATITIS B VIRUS WITH THE HELP OF ANTI-VIRUS AGENTS
EA200971041A1 (en) NEW PEPTIDE HEPATITIS C VIRUS REPLICATION INHIBITORS
EA200971026A1 (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
EA202192512A1 (en) FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR HBV DISEASES
WO2021055425A3 (en) Functionalized heterocycles as antiviral agents
EA202091113A1 (en) NEW HIGHLY ACTIVE AMINOTHIAZOL SUBSTITUTED INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
EA201591328A1 (en) HETEROCYCLED SUBSTITUTED TETRICYCLIC COMPOUNDS AND METHODS OF THEIR USE FOR THE TREATMENT OF VIRAL DISEASES
EA202191219A1 (en) NEW UREA-6,7-DIHYDRO-4H-PYRAZOLO [1,5-a] PYRAZINES, ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
EA202191223A1 (en) NEW 6,7-DIHYDRO-4H-PYRAZOLO [1,5-a] PYRAZINE-INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
EA202191216A1 (en) NEW 6,7-DIHYDRO-4H-PYRAZOLO [1,5-a] PYRAZINE-INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
PH12021550632A1 (en) Monomer and multimeric anti-hbv agents
MX2022006742A (en) Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives.
MX2021010145A (en) Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases.
EA202191218A1 (en) NEW UREA-6,7-DIHYDRO-4H-PYRAZOLO [1,5-a] PYRAZINES, ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
EA202191404A1 (en) FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
EA202191220A1 (en) NEW UREA-6,7-DIHYDRO-4H-PYRAZOLO [4,3-c] PYRIDINES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
EA201892732A1 (en) ANTI-VIRUS AGENTS FOR THE TREATMENT OF HEPATITIS B
EA201892004A1 (en) ANTIVIRAL AGENTS FOR THE TREATMENT OF HEPATITIS B